

From: [James Maloney](#)
To: [Riggins, Patrick](#)
Subject: RE: 125590/0/42 Information Request
Date: Wednesday, October 31, 2018 4:54:04 PM
Attachments: [1.11.1 IR final 29Oct2018.pdf](#)
[RI002 BLA 356h 0043 signed.pdf](#)
[RI-002 BLA Cover Letter 0043 signed.pdf](#)

APPROVED

By Patrick S. Riggins, PhD at 4:32 pm, Nov 16, 2018

Dr. Riggins,

Please see attached for our response to the information request below which will also be submitted via the Gateway today. Please let me know if you have any questions related to this submission.

Best Regards,

Jim

James Maloney
Senior Director, Regulatory Affairs



5800 Park of Commerce Blvd., NW
Boca Raton, FL 33487
Phone 561-989-5745
Fax 561-989-5898
jmaloney@admabio.com

From: Riggins, Patrick [mailto:Patrick.Riggins@fda.hhs.gov]
Sent: Wednesday, October 24, 2018 3:36 PM
To: James Maloney
Subject: 125590/0/42 Information Request

Jim,

I have the following information request. Please confirm your receipt of this request and also please send you response by next Wednesday, October 31, 2018.

1. Please confirm whether Immune Globulin Intravenous (human, RI-002, has been approved or marketed in any country. Please also supply any available post-marketing data.

Any questions, do not hesitate to let me know.

Regards,
Pat Riggins

Patrick S. Riggins, PhD
Division of Regulatory Project Management
Office of Tissues and Advanced Therapies
WO 71 Room 4261

10903 New Hampshire Ave.
Silver Spring, MD 20993
Phone: (240)402-8346
Fax: (301)595-1303

The information contained in this e-mail is confidential and/or proprietary to ADMA Biologics, Inc. and/or its subsidiaries and affiliates, and is intended to be received by the individual or entity named above for limited use, without copying, forwarding, disclosing or otherwise transmitting this message to any other party. Please return this email if you received this message in error or are unable to acknowledge and protect the confidential/proprietary nature of its contents.